Rocket Pharmaceuticals (RCKT) Operating Leases (2019 - 2026)

Rocket Pharmaceuticals (RCKT) has 8 years of Operating Leases data on file, last reported at $2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 19.45% year-over-year to $2.5 million; the trailing twelve-month figure through Mar 2026 stood at $2.5 million (down 19.45% YoY), and the FY2025 full-year result was $2.6 million, down 20.2% from the prior year.
• Operating Leases retreated to $2.5 million in Q1 2026, from $2.6 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $3.7 million in Q1 2024 to a low of $200000.0 in Q1 2023.
• A 5-year average of $2.4 million and a median of $2.9 million in 2025 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases tumbled 72.18% in 2023 and surged 1757.0% in 2024, its largest moves.
• Tracing RCKT's Operating Leases over 5 years: stood at $1.1 million in 2022, then surged by 173.25% to $3.0 million in 2023, then increased by 9.59% to $3.3 million in 2024, then retreated by 20.2% to $2.6 million in 2025, then dropped by 4.12% to $2.5 million in 2026.
• Business Quant data shows RCKT's Operating Leases at $2.5 million in Q1 2026, $2.6 million in Q4 2025, and $2.8 million in Q3 2025.